Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6–35 Months
10.3346/jkms.2019.34.e279
- Author:
Jee Hyun LEE
1
;
Hye Kyung CHO
;
Ki Hwan KIM
;
Jina LEE
;
Yae Jean KIM
;
Byung Wook EUN
;
Nam Hee KIM
;
Dong Ho KIM
;
Dae Sun JO
;
Hwang Min KIM
;
Yun Kyung KIM
Author Information
1. Department of Pediatrics, Korea University Ansan Hospital, Ansan, Korea. byelhana@korea.ac.kr
- Publication Type:Original Article
- Keywords:
Quadrivalent Influenza Vaccine;
Trivalent Influenza Vaccine;
Immunity;
Hemagglutination;
Children
- MeSH:
Antibodies;
Child;
Hemagglutination;
Humans;
Influenza Vaccines;
Influenza, Human;
Korea;
Orthomyxoviridae;
Vaccination;
Victoria
- From:Journal of Korean Medical Science
2019;34(46):e279-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The titer of influenza vaccine-induced antibodies declines over time, and younger children have lower immunogenicity and shorter duration of immunity. This study aimed to compare persistence of antibody at 6 months after influenza vaccination according to influenza virus strains, vaccine type, antigen dose, and primed status in children aged 6 to 35 months. METHODS: A total 124 healthy children aged 6 to 35 months were enrolled from September to December 2016 at 10 hospitals in Korea and randomly assigned to either a full dose of quadrivalent influenza vaccine or a half dose of trivalent influenza vaccine with Victoria B strain group. Hemagglutination inhibition antibody titers (that measure the seroprotection rates) were assessed for the recommended influenza strains at 6 months post vaccination. RESULTS: The seroprotection rates at 6 months for strains A (H1N1), A (H3N2), B/Yamagata, and B/Victoria were 88.7%, 97.4%, 36.6%, and 27.6%, respectively. The seroprotection rates for A (H1N1), A (H3N2) and B (Victoria) were 91.4%, 98.7% and 27.5% in a full dose of quadrivalent vaccine vs. 83.7%, 94.6% and 27.9% in a half dose trivalent vaccine, respectively. The seroprotection rate for the B (Yamagata) strain was 23.8% in the quadrivalent group and 14.0% in the trivalent group. CONCLUSION: Persistence of antibodies at 6 months was more favorable against the influenza A strains than against the B strains. Persistence of antibodies to additional B strain at 6 months was superior in the quadrivalent vaccine group. The immunity of primed children with different B strains was not superior to that of the unprimed group with another B strain.
